Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medjet

This article was originally published in The Gray Sheet

Executive Summary

Strategic alternatives under consideration by the ophthalmic device maker include sale of the company, one or more joint ventures, a merger or restructuring. Edison, New Jersey-based Medjet's first commercial product, the HydroBrush water jet-based keratome for ophthalmic epithelium removal, was 510(k) cleared in January 1998 (1"The Gray Sheet" Feb. 16, 1998, I&W-8). A new water jet microkeratome under development "is working well, and its advantages for use in refractive surgery have been evident to surgeons that have used it," Chairman Eugene Gordon says in a release. "We believe that exploring strategic options may hasten its introduction and help Medjet's common stock to more accurately reflect the quality of its technology"

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel